

Protecting the smallest from RSV infection  
from the day they arrive to the circle of life



Every day, every season,  
every year for 20 years



**ABBOSYNAGIS**  
**PALIVIZUMAB**

abbvie

Abbosynagis 100 mg/ml solution for injection, Prescribing Information, Mar 2016.

Abbosynagis is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease. Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season. Children less than 2 years of age and requiring treatment for bronchiolitis within the last 6 months. Children less than 2 years of age and with hemodynamically significant congenital heart disease. Important information: Palivizumab is contraindicated in patients with known hypersensitivity to any of the excipients, or other humanized monoclonal antibodies. Allergic reactions including very rare cases of anaphylaxis and anaphylactic shock have been reported following palivizumab administration. In some cases, fatalities have been reported. Medicinal products for the treatment of severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, should be available for immediate use following administration of palivizumab. A moderate to severe acute infection or febrile illness may warrant delaying the use of palivizumab; unless, in the opinion of the physician, withholding palivizumab entails a greater risk. A mild febrile illness, such as mild upper respiratory infection, is not usually reason to defer administration of palivizumab. As with any intramuscular injection, palivizumab should be given with caution to patients with thrombocytopenia or any coagulation disorder. Since the monoclonal antibody is specific for RSV, palivizumab is not expected to interfere with the immune response to vaccines. In clinical trials and post-marketing reports, the very common adverse reactions (≥ 1%) included rash and pyrexia.

For full information please see Abbosynagis Prescribing Information.

Full prescribing information can be received from Abbvie Biospharmaceuticals Ltd. Israel at 4 Hacharash street, Hod Hasharon 4524075. Tel: 09-72998600. Fax: 09-7260608.